|
UBR2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.61749510954701E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.451700004651E-08 |
| Normal-vs-Stage2 |
1.79435999999589E-05 |
| Normal-vs-Stage3 |
2.33789654302541E-11 |
| Normal-vs-Stage4 |
6.92220003539745E-09 |
| Stage1-vs-Stage2 |
6.694200E-01 |
| Stage1-vs-Stage3 |
1.548310E-02 |
| Stage1-vs-Stage4 |
7.302300E-02 |
| Stage2-vs-Stage3 |
2.117400E-01 |
| Stage2-vs-Stage4 |
2.852400E-01 |
| Stage3-vs-Stage4 |
9.632800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.19290149874973E-11 |
| Normal-vs-AfricanAmerican |
1.656260E-03 |
| Normal-vs-Asian |
3.16929999999438E-06 |
| Caucasian-vs-AfricanAmerican |
3.836600E-01 |
| Caucasian-vs-Asian |
3.569800E-01 |
| AfricanAmerican-vs-Asian |
7.735400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.12429999754582E-08 |
| Normal-vs-Female |
7.39499572688374E-11 |
| Male-vs-Female |
9.227400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.51630000006153E-07 |
| Normal-vs-Age(41-60Yrs) |
1.31480004661455E-09 |
| Normal-vs-Age(61-80Yrs) |
7.59909912773082E-11 |
| Normal-vs-Age(81-100Yrs) |
2.839400E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.149570E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.223670E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.932300E-02 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.503000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.659000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.478400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.620900E-03 |
| Classical-VS-Follicular |
1.415230E-01 |
| Classical-VS-Other |
2.938200E-01 |
| Classical-VS-Normal |
5.83719994562415E-09 |
| Tall-VS-Follicular |
7.368300E-02 |
| Tall-VS-Other |
6.149000E-01 |
| Tall-VS-Normal |
5.71820035766279E-10 |
| Follicular-VS-Other |
6.763200E-01 |
| Follicular-VS-Normal |
1.07680000027699E-07 |
| Other-VS-Normal |
3.538500E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
9.22899978661462E-10 |
| Normal-vs-N1 |
6.69399999875253E-08 |
| N0-vs-N1 |
5.577800E-01 |
|
|
